Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

ABT-773 (Abbott Laboratories).

L E Lawrence1

  • 1Microbiology Department, Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, CT 06492, USA. lawrencl@bms.com

Current Opinion in Investigational Drugs (London, England : 2000)
|September 27, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bacterial resistance.

IDrugs : the investigational drugs journal·2005
Same author

Quinolone update.

IDrugs : the investigational drugs journal·2005
Same author

38th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 24-27, 1998, San Diego, CA, USA.

Expert opinion on investigational drugs·2005
Same author

Efflux pumps in bacteria: overview, clinical relevance, and potential pharmaceutical target.

Expert opinion on investigational drugs·2005
Same author

39th Interscience Conference on Antimicrobial Agents and Chemotherapy of the American Society for Microbiology.

Expert opinion on investigational drugs·2005
Same author

Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).

Expert opinion on investigational drugs·2005
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

ABT-773, a novel macrolide antibacterial, shows promise for treating bacterial infections. It is effective against Streptococcus pneumoniae and Staphylococcus aureus, including resistant strains.

Area of Science:

  • Pharmacology
  • Infectious Diseases
  • Drug Development

Background:

  • ABT-773 is a macrolide antibacterial agent developed by Abbott Laboratories and Taisho Pharmaceutical Co Ltd.
  • It is being investigated for the potential treatment of bacterial infections.

Purpose of the Study:

  • To evaluate the efficacy and safety of ABT-773 in clinical trials.
  • To assess the in vitro and in vivo activity of ABT-773 against key bacterial pathogens.

Main Methods:

  • Phase I, II, and III clinical trials were conducted in the US and Japan.
  • In vitro and in vivo studies assessed activity against Streptococcus pneumoniae and Staphylococcus aureus.
  • Bioavailability and adverse effects were evaluated in healthy male subjects.

Related Experiment Videos

Main Results:

  • ABT-773 demonstrated good in vitro and in vivo activity against Streptococcus pneumoniae and Staphylococcus aureus.
  • The agent was highly potent against macrolide-resistant and invasive strains of S. pneumoniae.
  • Phase I trials in healthy males showed mild adverse effects, primarily gastrointestinal; bioavailability was unaffected by food.

Conclusions:

  • ABT-773 shows potential as a novel antibacterial agent, particularly for infections caused by resistant S. pneumoniae.
  • The drug's favorable safety and bioavailability profile supports its continued development.